Literature DB >> 21476439

WWOX oxidoreductase--substrate and enzymatic characterization.

Anna Sałuda-Gorgul1, Karolina Seta, Magdalena Nowakowska, Andrzej K Bednarek.   

Abstract

WWOX is a tumour suppressor gene that spans the common fragile site FRA16D. Analysis of the WWOX expression pattern in normal human tissues showed the highest expression in testis, prostate, and ovary. Its altered expression has been demonstrated in different tissues and tumour types. The WWOX gene encodes a 414-amino acids protein, which is the first discovered protein with a short-chain dehydrogenase/reductase (SDR) central domain and two WW domains at the NH2 terminus. Due to its potential role in sex-steroid metabolism, using two bacterial expression systems, we have cloned WWOX fusion proteins showing oxidoreductase activity in a crude extract, defined a course of enzymatic reactions for selected steroid substrates, and determined related Km values. Our results show that the SDR domain of the WWOX protein has dehydrogenase activity and is reactive both in the presence of NAD+ and NADP+ for all examined steroid substrates. On the other hand, with the same substrates and reduced cofactors (NADH and NADPH) reduction activity was not observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476439

Source DB:  PubMed          Journal:  Z Naturforsch C J Biosci        ISSN: 0341-0382


  11 in total

Review 1.  Structural insights into the functional versatility of WW domain-containing oxidoreductase tumor suppressor.

Authors:  Amjad Farooq
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-07

Review 2.  Alteration of WWOX in human cancer: a clinical view.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Andrzej K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

Review 3.  WWOX, the chromosomal fragile site FRA16D spanning gene: its role in metabolism and contribution to cancer.

Authors:  Robert I Richards; Amanda Choo; Cheng Shoou Lee; Sonia Dayan; Louise O'Keefe
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-16

Review 4.  WWOX and metabolic regulation in normal and pathological conditions.

Authors:  Izabela Baryła; Katarzyna Kośla; Andrzej K Bednarek
Journal:  J Mol Med (Berl)       Date:  2022-10-22       Impact factor: 5.606

Review 5.  Molecular Functions of WWOX Potentially Involved in Cancer Development.

Authors:  Karim Taouis; Keltouma Driouch; Rosette Lidereau; François Lallemand
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 6.  WWOX Tumor Suppressor Gene in Breast Cancer, a Historical Perspective and Future Directions.

Authors:  Karolina Pospiech; Elzbieta Płuciennik; Andrzej K Bednarek
Journal:  Front Oncol       Date:  2018-08-28       Impact factor: 6.244

7.  Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes.

Authors:  Srinivasarao Repudi; Irina Kustanovich; Sara Abu-Swai; Shani Stern; Rami I Aqeilan
Journal:  EMBO Mol Med       Date:  2021-11-07       Impact factor: 12.137

8.  Cellular Expression and Subcellular Localization of Wwox Protein During Testicular Development and Spermatogenesis in Rats.

Authors:  Md Abdullah Al Mahmud; Maki Noguchi; Ayaka Domon; Yuki Tochigi; Kentaro Katayama; Hiroetsu Suzuki
Journal:  J Histochem Cytochem       Date:  2021-02-10       Impact factor: 2.479

Review 9.  The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism.

Authors:  Muhannad Abu-Remaileh; Rami I Aqeilan
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-08

10.  Expression and clinical significance of WWOX, Elf5, Snail1 and EMT related factors in epithelial ovarian cancer.

Authors:  Yakun Hu; Yuchen Yan; Yang Xu; He Yang; Lisha Fang; Yongli Liu; Xin Li; Qiang Li; Hongchao Yan
Journal:  Oncol Lett       Date:  2019-12-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.